Synthesis and cholinesterase inhibitory potential of 2-phenoxy-N-substituted-acetamide derivatives

Year 2023, Volume: 6 Issue: 1, 27 - 33, 01.07.2023

Kiana Harati Seyedeh Mahta Kiaei , Tina Mahdipour Amjad Zahra Nobavar Karar Shukur , Açelya Mavideniz , Tugba Ercetin , Hayrettin Ozan Gülcan

https://doi.org/10.54994/emujpharmsci.1211796

Abstract

The research studies worldwide on the identification of novel molecules having the potential to inhibit cholinesterase enzymes generated many compounds with promising results for some of them. Since there are limited number of drugs used in the treatment of Alzheimer's Disease in particular, the research studies continue. Within the scope of this study, four 2-phenoxy-N-substituted-acetamide derivatives were synthesized and their structures were identified employing spectroscopic techniques. The title molecules were further evaluated for their cholinesterase inhibitory potential in modified Ellman’s method. The results displayed that the compounds have moderate activity and the simple scaffold employed might be used in future studies for more promising compounds.

Keywords

2-phenoxy-N-substituted-acetamide derivatives, alzheimer, cholinesterase

References

• Blanke SR, Blanke RV (1984). The Schotten-Baumann reaction as an aid to the analysis of polar compounds: application to the determination of tris (hydroxymethyl) aminomethane (THAM). Journal of analytical toxicology, 8(5), 231-233.
• Ellman GL (1958). A colorimetric method for determining low concentrations of mercaptans. Archives of biochemistry and Biophysics, 74(2), 443-450.
• Erdogan M, Kilic B, Sagkan R I, Aksakal F, Ercetin T, et al. (2021). Design, synthesis and biological evaluation of new benzoxazolone/benzothiazolone derivatives as multi-target agents against Alzheimer’s disease. European Journal of Medicinal Chemistry, 212, 113124.
• Gulcan HO, Mavideniz A, Sahin MF, Orhan I E (2019). Benzimidazole-derived compounds designed for different targets of Alzheimer’s disease. Current Medicinal Chemistry, 26(18), 3260-3278.
• Gulcan HO, & Orhan IE (2021). Dual Monoamine Oxidase and Cholinesterase Inhibitors with Different Heterocyclic Scaffolds. Current Topics in Medicinal Chemistry, 21(30), 2752-2765.
• Gulcan HO, Unlu S, Banoglu E, Sahin MF, Kupeli E, et al. (2003). Synthesis of new 4-(5-chloro-2-oxo-3H-benzoxazol-3-yl) butanamide derivatives and their analgesic and anti-inflammatory properties. Turkish Journal of Chemistry, 27(4), 467-476.
• Pepeu G, & Giovannini M G (2009). Cholinesterase inhibitors and beyond. Current Alzheimer Research, 6(2), 86-96.
• Pillai JA, & Cummings J L (2013). Clinical trials in predementia stages of Alzheimer disease. Medical Clinics, 97(3), 439-457.
• Shukur K, Ercetin T, Luise T, Sippl C, Sirkecioglu W, et al. (2021). Design, synthesis, and biological evaluation of new urolithin amides as multitarget agents against Alzheimer's disease. Archiv der Pharmazie, 354(5), 2000467.
• Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J (2004). Cholinesterase inhibitors used in the treatment of Alzheimer’s disease. Drugs & aging, 21(7), 453-478.